Quantitative targeted absolute proteomics-based ADME research as a new path to drug discovery and development: methodology, advantages, strategy, and prospects.
about
How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusionOptimized approaches for quantification of drug transporters in tissues and cells by MRM proteomicsRecent advances in understanding hepatic drug transportUnderstanding the rules of the road: proteomic approaches to interrogate the blood brain barrierChallenges of using in vitro data for modeling P-glycoprotein efflux in the blood-brain barrier.Role of (drug) transporters in imaging in health and disease.Quantitative targeted proteomics for membrane transporter proteins: method and application.Internal standard strategies for relative and absolute quantitation of peptides in biological matrices by liquid chromatography tandem mass spectrometry.The role of quantitative ADME proteomics to support construction of physiologically based pharmacokinetic models for use in small molecule drug development.Advances in Proteomic Technologies and Its Contribution to the Field of CancerIdentification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based ProteomicsPhysiologically based pharmacokinetic modelling of drug penetration across the blood-brain barrier--towards a mechanistic IVIVE-based approachMass spectrometry-based targeted proteomics as a tool to elucidate the expression and function of intestinal drug transporters.Advances in the proteomic discovery of novel therapeutic targets in cancer.Abundance of Hepatic Transporters in Caucasians: A Meta-Analysis.The Promises of Quantitative Proteomics in Precision MedicineMass spectrometry-based targeted quantitative proteomics: achieving sensitive and reproducible detection of proteins.Absolute abundance and function of intestinal drug transporters: a prerequisite for fully mechanistic in vitro-in vivo extrapolation of oral drug absorption.The impact of DNA methylation technologies on drug toxicology.Quantitative targeted proteomics for understanding the blood-brain barrier: towards pharmacoproteomics.Structure and function of BCRP, a broad specificity transporter of xenobiotics and endobiotics.Translational value of liquid chromatography coupled with tandem mass spectrometry-based quantitative proteomics for in vitro-in vivo extrapolation of drug metabolism and transport and considerations in selecting appropriate techniques.Re-engineering therapeutic antibodies for Alzheimer's disease as blood-brain barrier penetrating bi-specific antibodies.Major involvement of Na(+) -dependent multivitamin transporter (SLC5A6/SMVT) in uptake of biotin and pantothenic acid by human brain capillary endothelial cells.High performance enzyme kinetics of turnover, activation and inhibition for translational drug discovery.Differences in transport mechanisms of trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid in inflammation, prostate cancer, and glioma cells: comparison with L-[methyl-11C]methionine and 2-deoxy-2-[18F]fluoro-D-glucose.Attenuation of phosphorylation by deoxycytidine kinase is key to acquired gemcitabine resistance in a pancreatic cancer cell line: targeted proteomic and metabolomic analyses in PK9 cells.Virtual Screening for Potential Inhibitors of CTX-M-15 Protein of Klebsiella pneumoniae.PBPK modeling of irbesartan: incorporation of hepatic uptake.The use of a rapid MS-based method for the quantification of the CYP 3A4 protein directly from hepatocyte cell lysate for CYP induction studies.Virtual screening of potential inhibitor against FtsZ protein from Staphylococcus aureus.A study protocol for quantitative targeted absolute proteomics (QTAP) by LC-MS/MS: application for inter-strain differences in protein expression levels of transporters, receptors, claudin-5, and marker proteins at the blood-brain barrier in ddY, FVQuantitative analysis of cytochrome P450 isoforms in human liver microsomes by the combination of proteomics and chemical probe-based assay.Quantitative targeted absolute proteomics of rat blood-cerebrospinal fluid barrier transporters: comparison with a human specimen.Species differences of organic anion transporters involved in the renal uptake of 4-amino-3-chlorophenyl hydrogen sulfate, a metabolite of resatorvid, between rats and dogs.Large-scale multiplex absolute protein quantification of drug-metabolizing enzymes and transporters in human intestine, liver, and kidney microsomes by SWATH-MS: Comparison with MRM/SRM and HR-MRM/PRM.Expression of periaxin (PRX) specifically in the human cerebrovascular system: PDZ domain-mediated strengthening of endothelial barrier function.Drug transport across the blood-brain barrier
P2860
Q24273350-3AD302F2-5C98-4A06-B7E1-328BC6578243Q26851693-8C016440-4802-448B-926C-71879FABF692Q28077066-4955B361-4EDD-475B-8234-947271165BBEQ28081782-C22A9930-AEEA-4201-B45E-2D763181DE59Q30651426-AF195CB1-33BF-488C-8C5D-6053CA2CECDAQ30854787-D201F392-2AB1-4322-B28F-4A3D23B24E4BQ33803962-4B6E3754-F030-4941-A5EF-4E7EE3F5FAF2Q34310103-D444AD8F-AF17-4FC8-8D0D-999E5FD87FBDQ35560052-7019D8B4-38D8-40B9-8F30-CC24D7CA89DAQ36112651-D3CBA295-EAE3-408B-90A6-E22642EBC79FQ36118351-A508F832-2C2B-4F89-9D41-29BC8B572608Q37207750-C3AED3FA-110D-41E9-8A35-131CA6A8DA2BQ37207759-DDA2E828-5FC5-41A9-A10F-D8A0449F8420Q37260569-C7335389-D811-4D30-8A48-9160AB555015Q37279044-E4CFCE0B-2D6C-42A5-9768-5D5382E6604AQ37647264-DB248F6E-DCB8-4618-9FF6-A882BA49F613Q38009277-5C800C90-EA9F-4C6B-B97E-DC40D8ADC2C6Q38038547-F55B11BC-5C1B-4001-A78F-B51953C1FB07Q38198707-7E8ACE76-4474-4469-B714-561B43FF8909Q38202164-85D8C0F8-518B-4511-97DE-1217B3862A75Q38207943-444F0734-00BD-4BC4-ABA6-519FFF7CEBEAQ38537236-55A75C8A-94DF-4EAE-9145-CA137D726E07Q38826744-EA6E7EAB-599B-4F78-80EC-90C42A1CF606Q38895031-3DFFEFFA-D409-4FDE-8E48-AEDAA562DDD4Q38991583-FFBCAAD8-4C08-462E-B9F2-40BCD0099CE7Q39077194-1298ED5C-6D16-401C-BEB4-D172C0EB3117Q39379544-6038A1EC-6C1D-44BA-B795-82A10C5020BDQ40259704-9931011F-09A1-4982-8093-DD657081744DQ40875739-0F0B5A5A-47E5-40BC-86C9-DBCAD1C89755Q41656544-C56D23E7-DD0E-4633-8FD4-179048AF3683Q41675315-9FAECD1C-97B0-477B-A675-F35B9A28149AQ42024145-45EEDAF7-2AA8-4C2F-B641-8983BFF241F2Q46709200-DE5F2ACF-DEA7-4484-9D8D-087173D73BF9Q48189282-511D412D-6CA8-4FA4-9AAB-9C1ABD2D2766Q48627815-0BE51BCF-B6ED-467C-BD1A-F7B386DF86D6Q53048764-D685C0AC-3A1E-436F-9C89-92E6FFF6BF2BQ55686313-6ADDFA07-EB7F-4F1B-9D26-10AC08EB72D6Q57677287-FF036059-D3E6-4F3B-ACE5-A8C3A60B48C8
P2860
Quantitative targeted absolute proteomics-based ADME research as a new path to drug discovery and development: methodology, advantages, strategy, and prospects.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Quantitative targeted absolute ...... ages, strategy, and prospects.
@en
Quantitative targeted absolute ...... ages, strategy, and prospects.
@nl
type
label
Quantitative targeted absolute ...... ages, strategy, and prospects.
@en
Quantitative targeted absolute ...... ages, strategy, and prospects.
@nl
prefLabel
Quantitative targeted absolute ...... ages, strategy, and prospects.
@en
Quantitative targeted absolute ...... ages, strategy, and prospects.
@nl
P2093
P50
P356
P1476
Quantitative targeted absolute ...... tages, strategy, and prospects
@en
P2093
Sumio Ohtsuki
Tetsuya Terasaki
Yasuo Uchida
Yoshiyuki Kubo
P304
P356
10.1002/JPS.22612
P407
P577
2011-05-10T00:00:00Z